Introduction: Ototoxicity, involving damage to the cochlear and vestibular structures
of the inner ear, is a complication of pharmacotherapy. Hearing loss and balance
disorders caused by medications are of particular clinical significance because they
significantly impair the quality of life in adults and speech development in children.
Objective: We aim to summarize current knowledge on ototoxic drugs and hearing
protection strategies. Material and methods: We reviewed the scientific literature
published from 2004 to mid-2025. Results: The main groups of ototoxic drugs
include aminoglycosides, loop diuretics, platinum-based compounds, salicylates/
Non-steroidal anti-inflammatory drugs (NSAIDs), antimalarial agents, and
immunotherapies. Ototoxicity is often irreversible, especially with aminoglycosides
and platinum compounds. This information is critical in children and in patients
treated for drug-resistant tuberculosis, because the risk may be increased and the
effects can be long-lasting. To minimize irreversible damage, primary otoprotection
efforts focus on reducing exposure and on early detection of warning signs.
Methods include modifying dose schedules and preserving renal function to
prevent drug accumulation. Patients should limit their noise exposure and have
regular audiological examinations. Sodium thiosulfate is currently the only
otoprotective drug with strong clinical data and is approved in selected pediatric
indications. It is administered after cisplatin, with a delay, to reduce ototoxicity
while preserving the antitumor effect. Conclusions: It is essential to apply
otoprotective strategies consistently. Sodium thiosulfate may be considered in
selected patients. Research into new otoprotective agents should be continued.
Keywords: ototoxicity; drug-induced hearing loss; cisplatin; aminoglycosides;
otoprotection
